Johnson & Johnson’s subcutaneous Tremfya holds potential to set new standard in Crohn’s disease… EP News Bureau Oct 21, 2024 Tremfya's subcutaneous formulation may offer new flexibility for Crohn's disease treatment, positioning it as a key contender in…
Novel therapies to drive Crohn’s disease market growth across 8MM to $15 bn by 2032: GlobalData EP News Bureau Nov 3, 2023 An anticipated 11 assets in the late-stage pipeline will enter the CD market during the forecast period
